Sensitivity analysis of different HER2 clone numbers for detecting HER2 low and ultra-low expression in invasive breast cancer

被引：0
作者：
Liu, Y. [1 ]
Shang, J. [1 ]
He, J. [1 ]
Ding, Y. [1 ]
Li, J. [1 ]
机构：
[1] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
来源：
VIRCHOWS ARCHIV | 2024年 / 485卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
E-PS-02-05
引用
收藏
页码：S197 / S198
页数：2
相关论文
共 50 条
  • [41] HER2-Low Breast Cancer Can Be Visualized by HER2 PET Reply
    Seban, Romain-David
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (11) : 1841 - 1842
  • [42] HER2/neu in the management of invasive breast cancer
    Meric, F
    Hung, MC
    Hortobagyi, GN
    Hunt, KK
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2002, 194 (04) : 488 - 501
  • [43] Proliferation Index in "HER2 Low" Metastatic Breast Cancer
    Hrizat, A. S.
    Brachtel, E.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 160 : S13 - S14
  • [44] Proliferation Index in "HER2 Low" Metastatic Breast Cancer
    Hrizat, A. S.
    Brachtel, E.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 160 : S13 - S14
  • [45] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Sasagu Kurozumi
    Mary Padilla
    Masafumi Kurosumi
    Hiroshi Matsumoto
    Kenichi Inoue
    Jun Horiguchi
    Izumi Takeyoshi
    Tetsunari Oyama
    Jim Ranger-Moore
    D. Craig Allred
    Eslie Dennis
    Hiroaki Nitta
    Breast Cancer Research and Treatment, 2016, 158 : 99 - 111
  • [46] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Kurozumi, Sasagu
    Padilla, Mary
    Kurosumi, Masafumi
    Matsumoto, Hiroshi
    Inoue, Kenichi
    Horiguchi, Jun
    Takeyoshi, Izumi
    Oyama, Tetsunari
    Ranger-Moore, Jim
    Allred, D. Craig
    Dennis, Eslie
    Nitta, Hiroaki
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 99 - 111
  • [47] Evaluating the efficacy of neoadjuvant endocrine therapy in HER2 low vs. HER2 negative breast cancer: An NCBD analysis
    Chong, Esther G.
    Guo, Mengni
    Castillo, Dani Ran
    Bazan, Jose G.
    Yap, Kelly Khai Li
    Schultz-Costello, Katharine
    Wu, S. Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Analysis of truncated HER2 expression and activation in breast cancer
    Singh, S.
    Liu, X.
    Lee, T.
    Kirkland, R.
    Kuller, A.
    Ohrmund, L.
    Lin, F.
    Hanna, M.
    Kim, P.
    Ybarrondo, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
  • [50] The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status
    Nanae Horisawa
    Yayoi Adachi
    Daiki Takatsuka
    Kazuki Nozawa
    Yuka Endo
    Yuri Ozaki
    Kayoko Sugino
    Ayumi Kataoka
    Haruru Kotani
    Akiyo Yoshimura
    Masaya Hattori
    Masataka Sawaki
    Hiroji Iwata
    Breast Cancer, 2022, 29 : 234 - 241
12345